July 16th 2024
Previous studies on lipid levels and disease activity are inconsistent, and a causal relationship between lipid levels and IBD remains dubious.
Interleukin-2 Found to Be a Promising Pathway to Treat Ulcerative Colitis
August 7th 2023A small, open-label study seeds the idea that IL-2 in low doses might be another avenue for treating ulcerative colitis. Low doses may bolster anti-inflammatory T regulatory cells (Tregs) that are believed to lack sufficient expansion in the disease.
Read More
A Step Forward, Perhaps, for Safe Step Act and Exemptions from Step Therapy
June 19th 2023Legislation designed to smooth the path to exemptions from step therapy has been incorporated into the Pharmacy Benefit Reform Act, one of several bills targeting pharmacy benefit managers that is making legislative headway in the Senate.
Read More
Entyvio Found To Be Effective at Relieving Chronic Pouchitis After UC Surgery
April 19th 2023Patients treated with the gut-selective monoclonal antibody were three times more likely to achieve remission of inflammation of ileal pouch-anal anastomosis, an alternative to a life-long colostomy bag after colectomy.
Read More
University of Miami Researchers Receive $2.9 Million to Study IBD Genetics in Hispanic Population
February 3rd 2023Research by Maria T. Abreu, M.D., and Jacob McCauley, Ph.D., should help fill a gap in the research of the genetics of inflammatory bowel disease, including ulcerative colitis.
Read More
For Ulcerative Colitis, Two First-In-Class Candidates and an Interleukin-23 Competition
February 1st 2023A Swedish and a French company have treatments with novel mechanisms of action in late-stage development. Meanwhile, AbbVie, Janssen and Eli Lilly are vying to get the first interleukin-23 inhibitor for ulcerative colitis on the market.
Read More